Eric Venker - 07 Apr 2026 Form 4 Insider Report for Immunovant, Inc. (IMVT)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: IMVT
Reported as of: 07 Apr 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 09 Apr 2026, 16:13:44 UTC
Prior SEC filing: 03 Apr 2026
Next SEC filing: 22 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ Tiago Girao, Attorney-in-Fact for Eric Venker

Key filing fact

Eric Venker filed Form 4 for Immunovant, Inc. (IMVT) on 09 Apr 2026.

Key facts

This page summarizes Eric Venker's Form 4 filing for Immunovant, Inc. (IMVT).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 09 Apr 2026, 16:13.

Change

Previous filing in this sequence was filed on 03 Apr 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001801917 Primary reporting owner

Venker Eric

Relationship: Chief Executive Officer, Director
Address: C/O IMMUNOVANT, INC., 1000 PARK FORTY PLAZA, SUITE 210, DURHAM
Signature: /s/ Tiago Girao, Attorney-in-Fact for Eric Venker
Signature date: 09 Apr 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IMVT transaction

Common Stock

Award

Transaction value
Shares: +232,252
Change %: +1187%
Price: $0.000000^*
Shares after: 251,813
Date: 07 Apr 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IMVT transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +336,043
Change %
Price: $0.000000^*
Shares after: 336,043
Date: 07 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 336,043
Exercise price: $24.61
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan (the "Plan"). Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest as to 25% of the total shares on April 1, 2027 and the balance will vest in twelve (12) successive substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date.

Footnote F2

These options were granted pursuant to the Plan. The shares underlying the options will vest as to 25% of the total shares on April 1, 2027 and the balance will vest in thirty-six (36) successive substantially equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date.